MET and medullary thyroid gland carcinoma: Cabozantinib is another FDA-approved tyrosine kinase inhibitor targeting three important pathways: MET, vascular endothelial growth factor (VEGF), and rearranged during transfection (RET) for the treatment of metastatic medullary thyroid cancer.